EICHORCondition: Overweight · Obese · Type 1 Diabetes Mellitus · Sponsor: Carmot Therapeutics, Inc.
This study will evaluate the changes in glycemic control in overweight and obese adults with Type 1 Diabetes Mellitus after receiving CT-868 for 16 weeks. The effectiveness and safety of CT-868 will be compared to placebo. All participants will continue with their standard diabetes care using either an insulin pump (CSII) or multiple daily injections (MDI). Alongside their designated treatment, participants will receive guidance on managing their diabetes, including monitoring blood glucose levels and diet and exercise recommendations. Treatment assignments, either CT-868 plus insulin or placebo plus insulin will be randomly determined.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Male or female, 18 years of age or older at the time of signing informed consent * Have a documented clinical diagnosis of T1DM greater than or equal to 1 year before the Screening Visit * Body mass index greater than or equal to27.0 kg/m2 * Hemoglobin A1c (HbA1c) level between 7.0% and 10.0%, inclusive, at the Screening Visit Exclusion Criteria: * Diagnosis of Type 2 diabetes mellitus (T2DM) or any other types of diabetes, except T1DM * Experienced diabetic ketoacidosis (DKA) within 3 months prior to the Screening Visit * Experienced severe hypoglycemia (Level 3 as defined in the ADA Standards of Medical Care in Diabetes (ADA 2022) within 3 months prior to the Screening Visit
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| John Muir Physician Network Clinical Research Center | Concord, California, United States | — |
| Headlands Research- AMCR | Escondido, California, United States | — |
| University of Colorado - Barbara Davis Center for Diabetes | Aurora, Colorado, United States | — |
| Denver Endocrinology Diabetes and Thyroid Center | Englewood, Colorado, United States | — |
| Advent Health | Orlando, Florida, United States | — |
| Orlando Health Science Clinic, LLC | Orlando, Florida, United States | — |
| Innovative Research Institute | Port Charlotte, Florida, United States | — |
| Atlanta Diabetes Associates | Atlanta, Georgia, United States | — |
| Rocky Mountain Clinical Research, LLC- Idaho Falls, Idaho | Idaho Falls, Idaho, United States | — |
| Iowa Diabetes and Endocrinology Research Center | West Des Moines, Iowa, United States | — |
| MedStar Health Research Institute - Washington Hospital Center | Hyattsville, Maryland, United States | — |
| University of North Carolina Health Sciences at MAHEC | Asheville, North Carolina, United States | — |
+ 10 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06062069